REFERENCES
- Vokes EE, Bitran JD, Vogelzang NJ. Chemotherapy for non-small cell lung cancer. The continuing challenge. Chest 1991; 99: 1326–8.
- Bakowski MT, Crouch JD. Chemotherapy of non-small cell lung cancer: A reappraisal and a look to the future. Cancer Treat Rev 1983; 10: 159–72.
- Joss RA, Cavalli F, Goldhirsch A, et al. New agents in non-small cell lung cancer. Cancer Treat Rev 1984; 11: 205–36.
- Shepherd FA. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung can-cer: An overview. Anticancer Drugs 1995; 6: 19–25.
- Depierre A, Lemarie E, Dabouis G, et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991; 14: 115–9.
- Fukuoka M, Niitani H, Sizuki A, et al. A phase II study of CPT-11, a new derivative of camptothecins, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16–20.
- Rodriguez G, Valdivieso M, Vontoff D, et al. A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 382 (abstr. 1144).
- Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II stu dy in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 1997; 8: 525–9.
- Perng RP, Chen Y, Ming-Liu J, et al. Gemcitabine ver-sus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase III random-ized study. J Clin Oncol 1997; 15: 2097–102.
- Chang A, Kim K, Glick T, et al. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the ECOG results. J Nail Cancer Inst 1993; 85: 388–94.
- Murphy WK, Winn RJ, Fossella FW, et al. Phase II study of taxol in patients with advanced non-small cell lung cancer. J Nail Cancer Inst 1993; 85: 384–8.
- Fleming T. One-single multiple-testing procedure for phase II clinical trials. Biometrics 1982; 38: 143–51.
- Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA. Important advances in Oncology, Philadelphia: 2, 1988: 121-42.
- Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
- Gatzmeier U, Heckmayr M, Tischer-Neuhauss H, et al. Phase II study with paclitaxel in advanced inoperable non small cell lung cancer. Lung Cancer 1995; 12 (suppl. 2): 101-6.
- Hainsworth JD, Hopkins L, Thomas M, et al. Taxol administrated by one-hour infusion: preliminary results of a phase I/II study comparing two different schedules. Lung Cancer 1994; 11 (suppl. 11), abs 362: 96.
- Perez EA, Buckwalter CA. Sequence-dependent cyto-toxicity of etoposide and paclitaxel in human breast and lung cell lines. Cancer Chemother Pharmacol 1998; 41 (6): 448–52.
- Lilenbaum RC, Macmanus D, Engstrom C, Green M. Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies. Am J Clin Oncol 1998; 21 (2): 129–34.
- Ukena D, Berg M, Leutz M, Zell L, Schlimmer P, Sybrecht GW. A phase I study of paclitaxel in combination with etoposide in patients with stage IIB-IV non small cell lung cancer. Lung Cancer 1998; 19 (1): 31–36.
- Felip E, Massutti B, Camps C, et al. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non small cell lung cancer. Clin Cancer Res 1998; 4 (11): 2723–8.